A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...
A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.
Clinical Trials Arena on MSN22h
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback